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Poster Session I S245Other variables included in the multivariate (MV) analysis were age,
gender, diagnosis, disease status, degree of HLA-match, blood type
match, recipient CMV serology, use of TBI, infused NC, infused
CD34, CMV reactivation, and presence of aGVHD or cGVHD.
Results: The table shows the incidence and timing of infections in
the peri-transplant period. Sites of infection were reported from
day -90 to -1 and from day 0 to +100, respectively. Bacterial infec-
tions were bacteremia (52%,66%); ENT/pulmonary (21%,7%);
UTI (17%,6%); C. difficile (6%,19.5%); and other (4%,1.5%). Viral
infections were respiratory (56%,29%) and non-respiratory
(44%,71%). Fungal infections were fungemia (50%,73%) and si-
nus/pulmonary infection (50%,27%). On univariate (UV) analysis,
factors associated with a significant risk of aGVHD II-IV included:
infused CD34 cell dose.1 X105/kg (P5 0.04), non-malignant dis-
orders (P5 0.04), and presence of bacterial infection within 3
months pre-transplant (P5 0.04). High-infused CD34 remained
significant on MV analysis. None of the variables were significant
for aGVHD III-IV. Presence of aGVHD (P5 0.002) was the only
significant risk factor for cGVHD. Infused CD34# 1 X105/kg
(P5 0.01) and presence of fungal infection within 100 days post-
transplant (P\0.001) were significantly associated with poor EFS
at 1 year post-transplant.
Conclusion: Bacterial infection pre-transplant was a significant risk
factor for grade II-IV aGVHD on UV analysis. This may be related
to effective anti-bacterial therapy allowing shorter delays in proceed-
ing to transplant compared to either viral or fungal infections. This
could result in an increased systemic inflammatory milieu persisting
into the transplant period and adding to the cytokine storm. The
presence of fungal infection post-transplant was strongly associated
with increasedmortality. Of note, peri-transplant viral infections had
no influence on any of the outcomes.
Incidence and types of infection in the peri-transplant period.









infection (range)Bacterial 32 (41%) 221 (21 to -83) 49 (62%) 128 (0 to 190)
Fungal 4 (5%) 269 (219 to -90) 11 (14%) 118 (13 to 177)
Viral 34 (43%) 240 (21 to -89) 21 (27%) 124 (0 to 191)
Any 51 (65%) 231 (21 to -90) 70 (89%) 124 (0 to 191)Each type of infection (e.g. bacterial) was listed only once per patient,
even if they had several infections of that type.234
DIAGNOSTIC UTILITY AND COMPLICATIONS OF LIVER BIOPSY IN THE
PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT POPULATION
Oshrine, B.R.1, Lehmann, L.2, Duncan, C.N.2 1Children’s Hospital, Bos-
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Liver dysfunction (LD) is common following pediatric hema-
topoietic stem cell transplantation (HSCT). Often the etiology
of LD can be determined based on historical, physical exam,
laboratory, or imaging findings, but a liver biopsy may be nec-
essary to diagnosis the cause of LD and institute appropriate
therapy. We report our institution’s experience with liver biop-
sies in 356 consecutive HSCT patients from January 1, 2004
to December 31, 2008, to determine the clinical utility and
overall safety of this diagnostic modality. During the study pe-
riod, 16 (4.5%) patients underwent 18 liver biopsies, all of which
occurred following allogeneic HSCT. The median age at the
time of HSCT was 141.5 months, and the median time from
HSCT to liver biopsy was 205.5 days. All patients had transam-
inase elevation (median AST 208.5 units/L; ALT 331 units/L),
and 67% had hyperbilirubinemia (median total bilirubin
8.1 mg/dL; direct bilirubin 5.75 mg/dL). Imaging prior to biopsy
was performed in 17/18 cases. The most commonly utilized
method of biopsy was the imaging-guided percutaneous ap-proach, performed in 12/18 cases. Five biopsies were done trans-
jugularly and one was performed during open laparotomy. In all
cases a histopathologic diagnosis was made. The most common
diagnosis was graft-versus-host disease (GVHD), present in 15
of the 18 specimens, followed by iron overload (IO) (9/18).
Other histologic diagnoses included viral, toxic/metabolic injury,
early sinusoidal obstructive syndrome, and drug-induced damage.
In 12 cases, management was modified based on biopsy results.
Immunosuppression was added or adjusted to treat GVHD in 10
cases. In two cases phlebotomy or chelation therapy was recom-
mended for IO, despite this diagnosis being present in nine
specimens. Complications occurred after five biopsies (28%),
four of which were performed transjugularly. No complications
were observed after percutaneous biopsies. The most common
complication was intra-/extra-hepatic hemorrhage and need for
red blood cell transfusion (3/5). Two patients required transfer
to the intensive care unit for biopsy-related complications. In
two cases a second procedure was required to manage a bi-
opsy-related complication (both requiring hepatic artery emboli-
zation after transjugular biopsy). We conclude that while liver
biopsy successfully yields a diagnosis of the etiology of LD, it
is accompanied by high rates of complications, particularly
with the transjugular approach.235
A PILOT STUDY OF REDUCED INTENSITY CONDITIONING (RIC)WITH BU-
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Background: AlloSCT following conditioning with fludarabine,
busulfan, and alemtuzumab (BFA) in adult pts with AML/MDS
was safe and permitted durable donor engraftment (Ho et al, Blood,
2004). There is a paucity of data of RIC with fludarabine, busulfan
and rATG and none with alemtuzumab (BFA) in pediatric AlloSCT
recipients.
Objective: To determine the safety and percentage of mixed donor
chimerism following a BFA RIC AlloSCT in C&A.
Methods:We report results of a pilot study of BFA RICAlloSCT in
12 recipients (\21 yrs) withmalignant (n5 7; 5 average-risk, 2 poor-
risk: CML 4, APML 1, NHL 1, HTLV-LL 1), and non-malignant
diseases (n5 5: SAA 3, Scleroderma 1,Wolman’sDisease 1).Median
age 16 (2-20) yrs, 6F:6 M. Stem cell source: 2 unrelated cord blood
(UCB) (2 5/6), 1 unrelated BM (10/10), 2 related (1 6/6, 1 5/6) and
7 unrelated PBSC (3 8/10, 3 9/10, 1 10/10). Positive CD34 selection
was done in 5 unrelated PBSCT. RIC: fludarabine (180 mg/m2, 6
days), busulfan (16 mg/kg #4 yrs and 12.8 mg/kg for .4 yrs, 4
days, total 8 doses) + alemtuzumab (54 mg/m2, 5 escalating doses).
GVHD prophylaxis: FK506/MMF. STR loci were used to measure
donor chimerism.
Results:Median time to myeloid engraftment was 16d (16d vs. 16d
for unselected PBSC/BM/CB vs. selected PBSC recipients, ns); me-
dian time to platelet engraftment: 31d (27d vs. 35d for unselected
PBSC/BM/CB vs. selected PBSC recipients, ns). The probability
of developing $grade II, $grade III AGVHD and CGVHD was
41.6%, 25%, and 9% respectively. There was 1 primary graft failure
(GF), and no secondaryGF.Medianmixed donor chimerism day 100
and 1 yr: 99% and 96%, respectively; $90% of recipients achieved
$80%donor chimerism.The 3 yrOSwas 91.76 8% (100% forma-
lignant vs 80% for non-malignant diseases, ns). The probability of
3 yr OS for patients receiving CD34-selected PBSC was 100% and
receiving non-CD34-selected PBSC/BM/UCB was 85.7% (ns). 11
pts remain alive at median 2.8 (0.3-6.8) yrs. Only 1/12 developed
$grade III toxicity (liver grade IV). Incidence of transplant-related
mortality was 1/12 (9%). 1 patient died of IFI at day +40. Infectious
complications included: CVL bacteremia (6/12), 2 IFI and 3 other
